

# Accepted Manuscript

Combining Type I Interferons and 5-Aza-2'-Deoxycytidine to improve anti-tumor response against melanoma

Valeria Lucarini, Carla Buccione, Giovanna Ziccheddu, Francesca Peschiaroli, Paola Sestili, Rossella Puglisi, Gianfranco Mattia, Cristiana Zanetti, Isabella Parolini, Laura Bracci, Iole Macchia, Alessandra Rossi, Maria Teresa D'Urso, Daniele Macchia, Massimo Spada, Adele De Ninno, Annamaria Gerardino, Pamela Mozetic, Marcella Trombetta, Alberto Rainer, Luca Businaro, Giovanna Schiavoni, Fabrizio Mattei

PII: S0022-202X(16)32368-5

DOI: [10.1016/j.jid.2016.08.024](https://doi.org/10.1016/j.jid.2016.08.024)

Reference: JID 515

To appear in: *The Journal of Investigative Dermatology*

Received Date: 28 February 2016

Revised Date: 28 July 2016

Accepted Date: 18 August 2016

Please cite this article as: Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R, Mattia G, Zanetti C, Parolini I, Bracci L, Macchia I, Rossi A, D'Urso MT, Macchia D, Spada M, De Ninno A, Gerardino A, Mozetic P, Trombetta M, Rainer A, Businaro L, Schiavoni G, Mattei F, Combining Type I Interferons and 5-Aza-2'-Deoxycytidine to improve anti-tumor response against melanoma, *The Journal of Investigative Dermatology* (2016), doi: 10.1016/j.jid.2016.08.024.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



against melanoma.

Valeria Lucarini<sup>1#</sup>, Carla Buccione<sup>1#</sup>, Giovanna Ziccheddu<sup>1</sup>, Francesca Peschiaroli<sup>1</sup>, Paola Sestili<sup>1</sup>, Rossella Puglisi<sup>1</sup>, Gianfranco Mattia<sup>1</sup>, Cristiana Zanetti<sup>1</sup>, Isabella Parolini<sup>1</sup>, Laura Bracci<sup>1</sup>, Iole Macchia<sup>1</sup>, Alessandra Rossi<sup>1</sup>, Maria Teresa D'Urso<sup>1</sup>, Daniele Macchia<sup>1</sup>, Massimo Spada<sup>1</sup>, Adele De Ninno<sup>2</sup>, Annamaria Gerardino<sup>2</sup>, Pamela Mozetic<sup>4</sup>, Marcella Trombetta<sup>4</sup>, Alberto Rainer<sup>4</sup>, Luca Businaro<sup>2,3</sup>, Giovanna Schiavoni<sup>1§</sup>, Fabrizio Mattei<sup>1§\*</sup>

(1) Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

(2) Institute for Photonics and Nanotechnologies, Italian National Research Council, Rome, Italy

(3) UCBM-CNR Joint Lab for Nanotechnologies for the Life Sciences, Università Campus Bio-Medico di Roma, Rome, Italy.

(4) Unit of Tissue Engineering, Università Campus Bio-Medico di Roma, via Álvaro del Portillo 21, Rome, Italy.

(#) Contributed equally to this work. (§) Share senior co-authorship.

\*Address correspondence to: Dr. Fabrizio Mattei, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena, 299 - 00161 Rome, Italy. E-mail: fabrizio.mattei@iss.it.

**Keywords:** Combination therapy, Metastatic melanoma, Microfluidic devices, Decitabine, Type I Interferons.

**Running Title:** Decitabine improves Type I Interferons anti-tumor activity.

**Text word counts:** 3432

Download English Version:

<https://daneshyari.com/en/article/5649840>

Download Persian Version:

<https://daneshyari.com/article/5649840>

[Daneshyari.com](https://daneshyari.com)